MedPath

Adjunctive treatment with Aripiprazole for Risperidone –induced hyperprolactinemia

Not Applicable
Conditions
hyperprolactinemia induced by risperidone.
Hyperprolactinaemia
Registration Number
IRCT201307182181N6
Lead Sponsor
tabriz university of medical science
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
Female
Target Recruitment
40
Inclusion Criteria

inclusion criterias :
1.hyperprolactinemia
2. women in reproductive age
3.candidate for risperidone continuation

exclusion criterias:
1.previous amenorrhea
2.breastfeeding
3.pregnancy
4.renal failure
5. hypothyroidism
6. pituitary tumors
7. consumption of methyldopa, levodopa,cimethidine, strogen, opium derivatives

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Serum prolactin level. Timepoint: weekly for first 2 weeks then monthly for 3 months. Method of measurement: mg/dl.
Secondary Outcome Measures
NameTimeMethod
Drug side effect. Timepoint: the end of study. Method of measurement: patient interview.
© Copyright 2025. All Rights Reserved by MedPath